TACE联合RFA治疗原发性肝癌中长期生存率研究

摘要

Objective To explore the long-term survival of primary liver cancer of TACE combined with RFA. Methods A total of 100 cases were selected from June 2009 to June 2014 in our hospital treated with advanced hepatocellular carcinoma, according to a random number table method, they were randomly divided into treatment group radiofre-quency(RFA, 50 patients), and combined treatment group (TACE+RFA, 50 patients). Among them, the RF-treated patients were treated with RFA alone; the combined treatment group were taken RFA and TACE combined with combi-nation therapy. Follow-up for 12 to 50 months, the long-term efficacy and survival of the two groups of patients were compared. Results By analyzing and comparing two groups of patients after treatment, long-term survival of discovery, survival radiofrequency of treatment group was 1 to 60 months, the survival of patients combined treatment group was 2 to 89 months. 1-year survival rate of the combined treatment group was significantly higher than the radiofrequency treatment group(P<0.05); 3-year survival rate of the combined treatment group was significantly higher than radiofre-quency treatment group (P<0.05); 5-year survival rate of the combined treatment group was significantly higher than radiofrequency treatment group(P<0.05). The combined treatment group survival index statistics were better than the former, and the difference was statistically significant(P<0.05). Conclusion TACE and RFA combination therapy has a better therapeutic effect in improving long-term survival of patients on a more selective advantage for clinicians to use in the treatment of preference.%目的：探讨TACE联合RFA对原发性肝癌对患者长期生存率的影响。方法选取2009年6月~2014年6月于我院进行治疗的100例中晚期原发性肝癌患者。按照随机数字表法将其分为射频治疗组(RFA,50例)和联合治疗组(TACE+RFA,50例)。其中,射频治疗组患者单纯进行RFA治疗；联合治疗组患者采取RFA和TACE结合联合治疗。随访时间为12~50个月,比较两组患者的长期疗效及生存状况。结果通过分析对比两组患者治疗后远期生存状况发现,射频治疗组患者生存期为1~60个月,联合治疗组患者生存期为2~89个月。1年生存率联合治疗组显著高于射频治疗组(P<0.05)；3年生存率联合治疗组显著高于射频治疗组(P<0.05)；5年生存率联合治疗组显著高于射频治疗组(P<0.05)。联合治疗组统计的各项生存指标均优于前者,差异有统计学意义(P<0.05)。结论TACE和RFA联合治疗方案对于原发性肺癌患者具有更好的治疗效果,在提高患者远期生存状况方面更具有选择优势,适合临床医师在治疗时优先选择使用。